Fidarestat Sanwa Kagaku/NC Curex/Sankyo

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1233-1239

  Giannoukakis, Nick ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BROMO 2 FLUOROBENZYL)SPIRO[1,2,3,4 TETRAHYDROPYRROLO[1,2 A]PYRAZINE 4,3' PYRROLIDINE] 1,2',3',5' TETRAONE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; JTT 811; NK 860; PLACEBO; SORBINIL; UNCLASSIFIED DRUG; ZENARESTAT;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS FAT DISORDER;

ALDEHYDE REDUCTASE; ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0242658538     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. 178923 Clinical experience with sorbinil - An aldose reductase inhibitor. Pitts NE, Vreeland F, Shaw GL, Peterson MJ, Mehta DJ, Collier J, Gundersen K Metabolism 1986 35 4 Suppl 1 96-100
2. 219507 Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats. Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Naruse K, Sasaki H, Mizuno K, Matsubara A, Kakuta H et al Exp Physiol 1995 80 6 981-989
3. 219525 Effects of a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman-4,4′-imidazolidine]- 2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Mizuno K, Kato N, Matsubara A, Nakano K, Kurono M Metabolism 1992 41 10 1081-1086
4. 220012 Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro-[chroman-4,4′-imidazolidine] -2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M, Yagihashi S J Diabetes Complications 1994 8 1 27-32
5. 236269 Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model. Akita M, Mizuno K, Matsubara A, Nakano K, Kurono M Acta Med Okayama 1993 47 5 299-304
6. 279957 Direct measurement of polyol pathway activity in the ocular lens. Gonzalez RG, Barnett P, Aguayo J, Cheng HM, Chylack LT Jr Diabetes 1984 33 2 196-199
7. 368625 Effects of fidarestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: A 52-week placebo-controlled double-blind study. Hotta N, Ishii J, Sakamoto N Diabetes 2000 49 Suppl 1 Abs 142-OR
8. 371613 American Diabetes Association 60th Scientific Sessions (Part III), San Antonio, TX, USA. Hopfner R IDDB Meeting Report 2000 June 9-13
9. 373081 A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2′, 5′-dioxospiro[chroman-4,4′-imidazolidine]-2-carboxamide (fidarestat): Its absolute configuration and interactions with the aldose reductase by X-ray crystallography. Oka M, Matsumoto Y, Sugiyama S, Tsuruta N, Matsushima M J Med Chem 43 12 2479-2483
10. 394427 Drug development pipeline: Fidarestat. Kaken Pharmaceutical Co Ltd Company Communication 2000 December 20
11. 394738 Kaken, Sanwa Kagaku to comarket Japan's second ARI. Pharma Jpn 2000 1726 12
12. 407168 Accelerated intimal hyperplasia with hyperglycemia and its modification by an aldose reductase inhibitor. Goto M, Yamauchi Y, Azuma H Jpn J Pharmacol 2001 85 Suppl 1 Abs P-2
13. 408446 Impaired cyclic GMP production in corpus cavernosum of hyperglycemic rabbits and its reversal by aldose reductase inhibitor. Masuda H, Ichiyanagi N, Goto M, Azuma H Jpn J Pharmacol 2001 85 Suppl 1 Abs P-617
14. 408449 Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T, Kato K, Kasuya Y, Miwa K, Hotta N Exp Eye Res 2000 71 3 309-315
15. 408450 Inhibitory effects of fidarestat on aldose reductase and aldehyde reductase activity evaluated by a new method using HPLC with post-column spectrophotometric detection. Mizuno K, Suzuki T, Tanaka T, Taniko K, Suzuki T Biol Pharm Bull 2000 23 2 244-248
16. 408459 Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats. Kato N, Mizuno K, Makino M, Suzuki T, Yagihashi S Diabetes Res Clin Pract 2000 50 2 77-85
17. 416487 Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. Sobajima H, Aoki T, Sassa H, Suzuki T, Taniko K, Makino M, Mizuno K, Suzuki T Pharmacology 2001 62 4 193-199
18. 422744 Additional data required for Sanwa Kagaku's SNK-860. Pharma Jpn 2001 1761 12
19. 424510 Diabetic neuropathies: Features and mechanisms. Zochodne DW Brain Pathol 1999 9 2 369-391
20. 429316 NK Curex and Kaken to tie up for marketing of diabetic neuropathy treatment Aldos. Kaken Pharmaceutical Co Ltd Press Release 2000 December 07
21. 429531 Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: A 52-week multicenter placebo-controlled double-blind parallel group study. Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N Diabetes Care 2001 24 10 1776-1782
22. 433235 Kaken: Launch of fidarestat to be delayed due to additional studies. Pharma Jpn 2001 1774 11
23. 454547 Improvement of molecular indices of axonal regeneration by fidarestat (SNK-860) in experimental diabetic neuropathy. Tomlinson DR, Agthong S Diabetes 2002 51 Suppl 2 Abs 786-P
24. 455447 Sankyo, Sanwa Kagaku tie up on ARI, Ca antagonist. Pharma Jpn 2002 1797 11
25. 456909 Sanwa Kagaku Kenkyusho: Pipeline validation; SNK-860, SK-962, SK-983, SK-827. Sanwa Kagaku Kenkyusho Co Ltd Company Communication 2002 July 02
26. 476821 R&D pipeline. Sankyo Co Ltd Company World Wide Web Site 2002 November 30
27. 490218 Present status of the Sankyo Group - May 2003. Sankyo Co Ltd Company World Wide Web Site 2003 May 01
28. 492242 Safety and efficacy of fidarestat in patients with diabetic polyneuropathy. Arezzo J, Hohman T, Porte D, Raskin P Diabetes 2003 52 Suppl 6 Abs 24-OR
29. 493607 American Diabetes Association - 63rd Scientific Sessions (Part I) - Overnight Report, New Orleans, LA, USA. Evans L IDDB Meeting Report 2003 June 13-17
30. 498288 Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Obrosova IG, Michenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ Diabetes 2003 52 3 864-871
31. 498289 The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K, Kasuya Y, Yasuda Y, Kamiya H, Hotta N Diabetes Res Clin Pract 2003 60 1 1-9
32. 498293 Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. Asano T, Saito Y, Kawakami M, Yamada N J Diabetes Complications 2002 16 2 133-138
33. 501396 Type 2 diabetes: Epidemiology, pathophysiology, and diagnosis. Quinn L Nurs Clin North Am 2001 36 2 175-192
34. 501399 The pathophysiology of type 2 diabetes mellitus: An overview. Ostenson CG Acta Physiol Scand 2001 171 3 241-247
35. 501405 Matching treatment to pathophysiology in type 2 diabetes. Gerich JE Clin Ther 2001 23 5 646-659
36. 501408 Redefining the clinical management of type 2 diabetes: Matching therapy to pathophysiology. Gerich JE Eur J Clin Invest 2002 32 Suppl 3 46-53
37. 501409 Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Pugliese G, Tilton RG, Williamson JR Diabetes Metab Rev 1991 7 1 35-59
38. 501416 The involvement of aldose reductase in diabetic complications. Kinoshita JH, Nishimura C Diabetes Metab Rev 1988 4 4 323-337
39. 501418 Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Dunlop M Kidney Int Suppl 2000 77 S3-S12
40. 501422 Characterization of mRNA and genes for aldose reductase in rat. Nishimura C, Graham C, Hohman TC, Nagata M, Robison WG Jr., Carper D Biochem Biophys Res Commun 1988 153 3 1051-1059
41. 501426 Aldose reductase inhibitors: The end of an era or the need for different trial designs? Pfeifer MA, Schumer MP, Gelber DA Diabetes 1997 46 Suppl 2 S82-S89
42. 501450 Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients. Hamada Y, Kitoh R, Raskin P Diabetes 1991 40 10 1233-1240
43. 501453 Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. Vander Jagt DL, Hunsaker LA, Robinson B, Stangebye LA, Deck LM, J Biol Chem 1990 265 19 10912-10918
44. 501456 Identification and characterization of multiple osmotic response sequence in the human aldose reductase gene. Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS J Biol Chem 1997 272 26 16431-16437
45. 501458 Characterization of the human aldose reductase gene promoter. Wang K, Bohren KM, Gabbay KH J Biol Chem 1993 268 21 16052-16058
46. 502241 Neurobiology of diabetic neuropathy: How does glucose generate oxidative stress in peripheral nerve? Obrosova IG Int Rev Neurobiol 2002 50 3-35
47. 502243 An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense. Obrosova IG, Van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ FASEB J 2002 16 1 123-125
48. 502246 Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S Metabolism 1995 44 5 677-680
49. 502248 Contributions of polyol pathway to oxidative stress in diabetic cataract. Lee AY, Chung SS FASEB J 1999 13 1 23-30
50. 503110 Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats. Robison WG Jr., McCaleb ML, Feld LG, Michaelis OE IV, Laver N, Mercandetti M Curr Eye Res 1991 10 4 339-350
51. 503112 DNA-synthesis regulation and correlation with inositol trisphosphate levels in cultured bovine retinal capillary pericytes. Li WY, Tang L, Zhou Q, Qin M, Hu TS Exp Eye Res 1989 49 4 677-683
52. 503113 Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Hohman TC, Nishimura C, Robison WG Jr. Exp Eye Res 1989 48 1 55-60
53. 503116 Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: A comparative study with retinal capillary endothelial cells. Li W, Liu X, Yanoff M, Cohen S, Ye X Diabetologia 1996 39 5 537-547
54. 503117 Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. Mizutani M, Kern TS, Lorenzi M J Clin Invest 1996 97 12 2883-2890
55. 503266 Sorbitol pathway: Presence in nerve and cord with substrate accumulation in diabetes. Gabbay KH, Merola LO, Field RA Science 1966 151 707 209-210
56. 503274 The effect of ONO-2235 on the sorbitol content of ethyrocytes in patients with diabetic neuropathy. Shiget H, Nakano H, Nakai M, Mori H, Shigeta M, Takagi S, Kitagawa Y, Kajiyama S, Kano Y, Arai Y, Inoue Y et al. In: Polyol Pathway and Its Role in Diabetic Complications Eds: Sakamoto N, Kinoshita JH, Kador PF, Hotta N, Elsevier Science Publishers BV, Amsterdam, the Netherlands 1988
57. 504424 Pathophysiology of type 2 diabetes and its relationship to new therapeutic approaches. Bell D Diabetes Educ 2000 26 Suppl 4-7